These findings emphasize the necessity for continuous, long-term monitoring of patients receiving combination therapy with GLP-1 receptor agonists and metformin, regardless of treatment duration, to ensure timely identification and management of potential adverse events
Final results were never released
Players in the compounded GLP-1 market must rigorously review their product marketing language and brace for tighter oversight to confirm copycat GLP-1s are prescribed only under legitimate, physician-documented clinical criteria
Next, determine the initial concentration of the solution (C1)
Ro leans further into GLP-1s Ro, founded as Roman in 2017, has been helping patients treat obesity since 2020
As of April 2026, tirzepatide remains on the shortage list